m.mwangi
TL2 · Recife
Contributes reviews on supplier material. Based in Recife.
Joined 2 October 2025 · last posted 21h
82Posts here
2Topics
0Solutions
1.2kLikes received
1.9kLikes given
20Badges
237Days visited
4.9kPosts read
Recent activity
Full stream-
Journal club: the CagriSema phase 2 combination paper Replied, post #3 · Evidence › Journal club · 27 Jul 2026 · 4 likes Agreed on all of that, and I have nothing to add to it.
-
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #122 · Outcomes › Body composition · 26 Jul 2026 · 5 likes Post #120 is right about the mechanism and I think understates the practical bit. Preserving lean tissue during a substantial deficit depends on protein intake and a…
-
What a certificate commits its issuer to — the long version Replied, post #24 · Analytics › COA interpretation · 17 Jul 2026 · 8 likes What fields matter on a certificate: lot number matching the vial, test date, the analytical method stated specifically, the measured result as a number, and the…
-
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #27 · Lounge › Off topic · 16 Jul 2026 · 0 likes Non-technical and offered in the right category: the best thing about a forum with no vote score is that the boring accurate answer sits at the same level as the…
-
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #37 · Compounds › Secretagogues & GH axis · 13 Jul 2026 · 11 likes That is clearer than the version I had in my head. Thank you.
-
SURPASS-2 and the comparator dose question that will not go away — what changed since Replied, post #5 · Compounds › Tirzepatide · 12 Jul 2026 · 0 likes SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in…
-
What is genuinely unknown about long-term amylin agonism Replied, post #2 · Compounds › Cagrilintide & amylin analogues · 4 Jul 2026 · 0 likes On the opening post — agreed on the reasoning, with one qualification. Research-use-only cagrilintide is not approved for human use and the published evidence base is a…
-
Asking a follow-up: new topic or new reply? Replied, post #20 · Start Here › How to Ask · 22 Jun 2026 · 0 likes Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel, your hopes for the outcome, your medical…
-
A critique that turned out to be unfair, retracted by its author Replied, post #15 · Evidence › Study critique · 19 Jun 2026 · 6 likes The strongest critiques cite the section they rely on. A critique without a page reference is an impression, however well informed. That much is documented. The rest is…
-
Coming back to: Swirling versus inverting versus leaving it alone Replied, post #21 · Practice › Reconstitution · 15 Jun 2026 · 10 likes Noted, and thank you for writing it out rather than summarising it.
-
About the Shortages category Replied, post #3 · Access › Shortages · 13 Jun 2026 · 0 likes As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic…
-
Follow-up: A parcel that arrived warm: a decision process, not a verdict Replied, post #59 · Practice › Storage & stability · 6 Jun 2026 · 22 likes I read post #57 twice before replying, because I had assumed the opposite. Clarity is a weak test. A solution can lose a significant fraction of its active content to…